Epizyme (EPZM) Misses Q4 EPS by 7c

Epizyme (NASDAQ: EPZM) reported Q4 EPS of ($0.65), $0.07 worse than the analyst estimate of ($0.58). Revenue for the quarter came in at $8.38 million versus the consensus estimate of $6.19 million.

2021 Financial Guidance:

• Based on its current operating plans, Epizyme expects its current cash runway to extend into 2023. Additionally, the Company expects its non-GAAP adjusted operating expenses for 2021 to be between $235 and $255 million.
• A reconciliation of non-GAAP adjusted financial measures directly comparable to GAAP financial measures is presented in the table attached to this press release.

For earnings history and earnings-related data on Epizyme (EPZM) click here.

You May Also Be Interested In

• Outlook Therapeutics (OTLK) Misses Q3 EPS by 9c
• Acurx Pharmaceuticals (ACXP) Tops Q2 EPS by 4c
• Prosensa Holding N.V. (RNA) Reports Q2 Loss of $1.18